Skip to main content
OpenTrials

Clinical trial condition

Hematologic Diseases

Explore clinical trials studying Hematologic Diseases. Study availability and eligibility vary by location and protocol.

15,467 public trials 2,848 recruiting studies
Refine in advanced search Browse all conditions

Hematologic Diseases trial results

Active, not recruiting

Agriculture Health Study

NCT00352924

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Genital Diseases, +25 more
Locations
  • Research Triangle Institute Research Triangle Park, North Carolina, United States
View Trial Details
Active, not recruiting

A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma

NCT06577025

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • City of Hope Duarte, California, United States
  • University of California San Francisco San Francisco, California, United States
  • University of Iowa Hospital and Clinics Iowa City, Iowa, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
View all 16 locations
View Trial Details
Active, not recruiting

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT02048813

Conditions
Anemia, Chronic Disease, Chronic Lymphocytic Leukemia, +16 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
  • Anchorage Radiation Therapy Center Anchorage, Alaska, United States
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
View all 781 locations
View Trial Details
Active, not recruiting

A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma

NCT06934044

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Sun yat-sen University Cancer Center Guangzhou, Guangdong, China
  • Tianjin Institute of Hematology & Blood Diseases Hospital Tianjin, Tianjin Municipality, China
  • The First Affiliated Hospital of Nanchang University Nanchang, China
  • The First Affiliated Hospital of Wenzhou Medical University Wenzhou, China
View Trial Details
Active, not recruiting

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

NCT06208150

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • UCSF Fresno Clovis, California, United States
  • UCLA Santa Monica, California, United States
  • Yale University School Of Medicine New Haven, Connecticut, United States
  • Medical Oncology Hematology Consultants, PA Newark, Delaware, United States
View all 242 locations
View Trial Details
Active, not recruiting

A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

NCT05424822

Conditions
Chronic Disease, Disease Attributes, Hematologic Diseases, +15 more
Locations
  • City of Hope Duarte, California, United States
  • Icahn School of Medicine at Mount Sinai New York, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
  • Sarah Cannon Research Institute Nashville, Tennessee, United States
View all 29 locations
View Trial Details
Active, not recruiting

A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma

NCT05083169

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • University of Alabama Birmingham Birmingham, Alabama, United States
  • City of Hope Duarte, California, United States
  • Stanford University Medical Center Stanford, California, United States
  • Yale University New Haven, Connecticut, United States
View all 176 locations
View Trial Details
Active, not recruiting

Evaluation of a Comprehensive School Health Programme in Zambia

NCT06560853

Conditions
Anemia, Diarrhea, Hematologic Diseases, +10 more
Locations
  • Chingola District Education Board Chingola, Copperbelt, Zambia
  • Luanshya District Education Board Luanshya, Copperbelt, Zambia
  • Masaiti District Education Board Masaiti, Copperbelt, Zambia
  • Kawambwa District Education Board Kawambwa, Luapula Province, Zambia
View Trial Details
Active, not recruiting

Pyruvate Kinase Deficiency Global Longitudinal Registry

NCT03481738

Conditions
Anemia, Anemia, Hemolytic, Anemia, Hemolytic, Congenital, +7 more
Locations
  • Phoenix Childrens Hospital Phoenix, Arizona, United States
  • Arkansas Children's Hospital Little Rock, Arkansas, United States
  • University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
  • Children's Hospital of Orange County Orange, California, United States
View all 52 locations
View Trial Details

Related conditions